...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith funding???

KOO - I'm not sure if you are asking me a question and if so, exactly what. You might be totally correct on what you stated but that is money that Zenith has to give to RVX putting them into debt. It also has to show in their financial statements. It shows as US$2.010 million of net R&D and US$573,000 as General & Administrative for US$2.583 million divided by three for US$860,000/month over the quarter ending Jan. 31st. Is that what you were questioning?

From Jan. 31st to June 30th is 5 months at US$860,000/month or the 9 month average burn of US$800,000 which gives US$4mm - US$4.3 million of burn only covered by $83,000 cash at Jan. 31st.

Share
New Message
Please login to post a reply